


WKYMVm Protein**A Potent Agonist of FPR2 and FPR3 G-Protein Coupled Receptors****Catalog # PG10021****Specification****WKYMVm Protein - Product Information****WKYMVm Protein - Additional Information****Storage****-20°C****Precautions**

WKYMVm Protein is for research use only and not for use in diagnostic or therapeutic procedures.

WKYMVm Protein - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

WKYMVm Protein - Images

WKYMVm - Abgent WKYMVm activates Ca²⁺ transients in HL-60 cells. Cells were loaded with Fluo-3 AM. Changes in intracellular Ca²⁺ were detected via changes in Fluo-3 emission following application (indicated by arrow) of 1 μM WKYMVm (#PG10021), (green) compared to control (black, saline perfusion) and to the effect achieved after 30 minutes incubation with the specific FPR2 antagonist WRW4, (10 μM, blue).

WKYMVm Protein - Background

Chemotactic factors from both Gram-positive and Gram-negative bacteria are short peptides with N-formyl methionine at the N-terminus (extensively reviewed in reference 1). These peptides are released from bacteria during infection and activate formyl peptide receptor (FPR), a member of G-protein coupled receptors (GPCRs). In human, the FPR family consists mainly of three receptors, FPR1, FPR2/ALX (formerly FPRL1), and FPR3 (formerly FPRL2) which all couple to the Gi subtype of G-proteins and ultimately lead to the activation of phospholipase C and intracellular Ca^{2+} increase^{1,2}. WKYMVm is a selective agonist of the Formylpeptide receptors (FPR2 and FPR3) and was discovered by screening peptide libraries for their ability to stimulate inositol phosphates in lymphocyte cell lines^{3,4}. It is also an agonist of FPR1¹. FPR2 is expressed in the promyelocytic leukemia cell line HL-60 as well as in the chronic myelogenous leukemia cell line K562⁵. WKYMVm inhibited the infection of human peripheral monocyte-derived macrophages and CD41 T lymphocytes by strains of HIV-1, via sensitization of chemokine receptors (CXCR4 and CCR5), following FPR2 activation⁶.

WKYMVm Protein - References

1 . Ye, R.D. et al.(2009)Pharmacol. Rev.61,119.2 . Le, Y. et al.(2002)Trends Immunol. 23,541.3 . Le, Y. et al. (1999)J. Immunol.163,6777.4 . Christophe, T. et al. (2001)J. Biol. Chem. 276,21585.5 . See Applications for Anti-Human FPR2/ALX (extracellular).6 . Li, B.Q. et al. (2001)Blood97,2941.